@rouchelles.bsky.social
Thank you Irene Fernandez-Ruiz for this great piece of commentary in @natrevcardiol.nature.com on the IVORY trial published in @natmed.nature.com
Main paper can be found here:
rdcu.be/eX8W3
@ziadmallat.bsky.social @18fdg.bsky.social @vpd-hlri.bsky.social @medcambridge.bsky.social
Main paper can be found here:
rdcu.be/eX8W3
@ziadmallat.bsky.social @18fdg.bsky.social @vpd-hlri.bsky.social @medcambridge.bsky.social
New online! Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes #CardioSky
Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes
Nature Reviews Cardiology, Published online: 22 January 2026; doi:10.1038/s41569-026-01256-0Treatment with low-dose IL-2 increases regulatory T cell numbers and reduces arterial inflammation in patients with an acute coronary syndrome and residual systemic inflammation compared with placebo, according to findings from the IVORY trial.
dlvr.it
January 23, 2026 at 2:12 PM
Thank you Irene Fernandez-Ruiz for this great piece of commentary in @natrevcardiol.nature.com on the IVORY trial published in @natmed.nature.com
Main paper can be found here:
rdcu.be/eX8W3
@ziadmallat.bsky.social @18fdg.bsky.social @vpd-hlri.bsky.social @medcambridge.bsky.social
Main paper can be found here:
rdcu.be/eX8W3
@ziadmallat.bsky.social @18fdg.bsky.social @vpd-hlri.bsky.social @medcambridge.bsky.social
Reposted
Fresh off her @naturemedicine.bsky.social paper.
@rouchelles.bsky.social talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome.
Read more ⬇️
rdcu.be/eX8W3
@nihr.bsky.social
@royalpapworth.bsky.social
@rouchelles.bsky.social talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome.
Read more ⬇️
rdcu.be/eX8W3
@nihr.bsky.social
@royalpapworth.bsky.social
January 20, 2026 at 9:41 AM
Fresh off her @naturemedicine.bsky.social paper.
@rouchelles.bsky.social talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome.
Read more ⬇️
rdcu.be/eX8W3
@nihr.bsky.social
@royalpapworth.bsky.social
@rouchelles.bsky.social talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome.
Read more ⬇️
rdcu.be/eX8W3
@nihr.bsky.social
@royalpapworth.bsky.social
Reposted
Please do have a listen to @rouchelles.bsky.social sharing her thoughts about her science, balancing a clinical academic career in cardiology with family life, & the importance of mentors and a supportive environment.
@nihr.bsky.social @royalpapworth.bsky.social @cam.ac.uk
@nihr.bsky.social @royalpapworth.bsky.social @cam.ac.uk
Fresh off her @naturemedicine.bsky.social paper.
@rouchelles.bsky.social talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome.
Read more ⬇️
rdcu.be/eX8W3
@nihr.bsky.social
@royalpapworth.bsky.social
@rouchelles.bsky.social talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome.
Read more ⬇️
rdcu.be/eX8W3
@nihr.bsky.social
@royalpapworth.bsky.social
January 20, 2026 at 11:49 AM
Please do have a listen to @rouchelles.bsky.social sharing her thoughts about her science, balancing a clinical academic career in cardiology with family life, & the importance of mentors and a supportive environment.
@nihr.bsky.social @royalpapworth.bsky.social @cam.ac.uk
@nihr.bsky.social @royalpapworth.bsky.social @cam.ac.uk
Thank you Elisa Martini for featuring the IVORY trial published in @natmed.nature.com in Nature Portfolio’s Nature CVR 🫀
Main paper: rdcu.be/eX8W3
Commentary: rdcu.be/eYyG6
@jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social
Main paper: rdcu.be/eX8W3
Commentary: rdcu.be/eYyG6
@jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social
January 19, 2026 at 2:26 AM
Thank you Elisa Martini for featuring the IVORY trial published in @natmed.nature.com in Nature Portfolio’s Nature CVR 🫀
Main paper: rdcu.be/eX8W3
Commentary: rdcu.be/eYyG6
@jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social
Main paper: rdcu.be/eX8W3
Commentary: rdcu.be/eYyG6
@jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social
Reposted
In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo.
https://www.nature.com/articles/s41591-025-04090-y
https://www.nature.com/articles/s41591-025-04090-y
January 17, 2026 at 5:40 PM
In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo.
https://www.nature.com/articles/s41591-025-04090-y
https://www.nature.com/articles/s41591-025-04090-y
Reposted
Amazing to be part of this team - please read the paper and let us know what you think! @rouchelles.bsky.social
The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
January 15, 2026 at 10:18 AM
Amazing to be part of this team - please read the paper and let us know what you think! @rouchelles.bsky.social
Reposted
A potential breakthrough in heart disease
Cambridge medics tested a low-dose drug that ⬇️inflammation in blood vessels by ⬆️ protective immune cells. This mechanism won the 2025 Nobel Prize for Medicine
Over 2 years Drug group: 0 events, placebo 11%
www.nature.com/articles/s41...
#HeartHealth
Cambridge medics tested a low-dose drug that ⬇️inflammation in blood vessels by ⬆️ protective immune cells. This mechanism won the 2025 Nobel Prize for Medicine
Over 2 years Drug group: 0 events, placebo 11%
www.nature.com/articles/s41...
#HeartHealth
Client Challenge
www.nature.com
January 11, 2026 at 3:56 PM
A potential breakthrough in heart disease
Cambridge medics tested a low-dose drug that ⬇️inflammation in blood vessels by ⬆️ protective immune cells. This mechanism won the 2025 Nobel Prize for Medicine
Over 2 years Drug group: 0 events, placebo 11%
www.nature.com/articles/s41...
#HeartHealth
Cambridge medics tested a low-dose drug that ⬇️inflammation in blood vessels by ⬆️ protective immune cells. This mechanism won the 2025 Nobel Prize for Medicine
Over 2 years Drug group: 0 events, placebo 11%
www.nature.com/articles/s41...
#HeartHealth
The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
January 12, 2026 at 7:05 PM
The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
January 12, 2026 at 6:30 PM
Reposted
Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation.
Learn More: www.nature.com/articles/s41...
Learn More: www.nature.com/articles/s41...
Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine
In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of ...
www.nature.com
January 8, 2026 at 1:56 PM
Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation.
Learn More: www.nature.com/articles/s41...
Learn More: www.nature.com/articles/s41...
Reposted
After 6 weeks of Rx patients with ACSs, low-dose IL-2 safely increases Tregcell levels and reduces arterial inflammation.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine
In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of ...
www.nature.com
January 8, 2026 at 11:25 AM
After 6 weeks of Rx patients with ACSs, low-dose IL-2 safely increases Tregcell levels and reduces arterial inflammation.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Delighted to share that the results of the IVORY trial were published in Nature Medicine: rdcu.be/eX8W3
This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.
This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.
Client Challenge
rdcu.be
January 11, 2026 at 10:23 PM
Delighted to share that the results of the IVORY trial were published in Nature Medicine: rdcu.be/eX8W3
This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.
This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.